Abbott India Limited (ABBOTINDIA) AI Stock Analysis

• Market Cap: ₹635.62B
• Dividend Yield: 1.6%
• Average Volume (3M): 628.00
• Price to Earnings (P/E): 43.6
• Beta (1Y): 0.64
• Revenue Growth: 11.17%
• EPS Growth: 17.22%
• Country: IN
• Employees: 3,814
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 172.30
• Shares Outstanding: 21,249,302
• 10 Day Avg. Volume: 806
• 30 Day Avg. Volume: 628
• PEG Ratio: 2.57
• Price to Book (P/B): 15.22
• Price to Sales (P/S): 10.05
• P/FCF Ratio: 67.16
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹37,000.00
• Price Target Upside: 24.59% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 67 Neutral
• Price Target: ₹32,829.00 ▲(10.55% Upside)

Abbott India Limited's strong financial performance is the primary driver of its overall stock score, supported by robust profitability and a solid balance sheet. However, technical indicators suggest bearish momentum, and the high P/E ratio indicates potential overvaluation, which tempers the overall score.

Abbott India Limited Business Overview & Revenue Model

Company Description

Abbott India Limited operates as a pharmaceutical company in India. It offers pharmaceutical products for various therapeutic areas, such as women's health, gastroenterology, metabolic, central nervous system, pain management, pre-term labor, vitamins, insomnia, vaccines, consumer health, etc. The company was formerly known as Knoll Pharmaceuticals Limited and changed its name to Abbott India Limited in July 2002. Abbott India Limited was incorporated in 1944 and is headquartered in Mumbai, India. Abbott India Limited is a subsidiary of Abbott Capital India Limited.

How the Company Makes Money

Abbott India generates revenue primarily through the sale of its pharmaceuticals and nutritional products, which are marketed under well-known brand names. The company has a diverse portfolio that includes prescription medicines, over-the-counter products, and nutritional products for infants and adults. Key revenue streams include sales from the pharmaceutical segment, which contributes significantly to the company's earnings, as well as revenues from its diagnostic and medical device segments. Abbott India also benefits from strategic partnerships with healthcare providers and institutions that enhance its market reach and penetration. Additionally, the company invests in research and development to innovate and expand its product offerings, which helps maintain a competitive edge in the market.

Abbott India Limited Financial Statement Overview

Summary

Abbott India Limited demonstrates strong financial health across income, balance sheet, and cash flow verticals. The company exhibits robust profitability, efficient asset utilization, and solid cash flow management, positioning it well for continued growth. The balance sheet is a particular strength due to low leverage and solid equity foundation.

Income Statement

Abbott India Limited showcases strong profitability with consistent revenue growth and robust margins. The gross profit margin has remained healthy, reflecting efficient cost management. Net profit margin has improved significantly, indicating strong bottom-line performance. EBIT and EBITDA margins also reflect operational efficiency, contributing to the positive outlook in this vertical.

Balance Sheet

The company maintains a solid balance sheet with a low debt-to-equity ratio, indicating prudent financial leverage. The equity ratio is strong, showcasing a substantial proportion of assets financed by equity, enhancing financial stability. The return on equity remains impressive, reflecting effective utilization of shareholder funds.

Cash Flow

Abbott India exhibits strong cash flow management with consistent free cash flow generation. While there is a slight decline in operating cash flow, the company maintains a healthy free cash flow to net income ratio, indicating efficient cash conversion. The free cash flow growth rate, although slightly volatile, remains positive, supporting future investments and shareholder returns.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	65.90B	64.09B	58.47B	53.47B	49.10B	43.08B
Gross Profit	29.97B	29.12B	26.14B	23.61B	22.42B	19.07B
EBITDA	20.30B	19.70B	16.98B	13.56B	11.61B	9.98B
Net Income	14.52B	14.14B	12.01B	9.49B	7.99B	6.91B
Balance Sheet
Total Assets	0.00	59.17B	51.93B	45.56B	42.24B	38.40B
Cash, Cash Equivalents and Short-Term Investments	31.13B	31.13B	21.18B	19.22B	27.35B	23.98B
Total Debt	0.00	1.97B	832.30M	1.13B	1.52B	1.53B
Total Liabilities	-42.33B	16.84B	14.95B	13.67B	14.04B	12.38B
Stockholders Equity	42.33B	42.33B	36.99B	31.89B	28.20B	26.02B
Cash Flow
Free Cash Flow	0.00	9.59B	11.64B	8.59B	9.04B	7.03B
Operating Cash Flow	0.00	10.12B	12.13B	8.93B	9.48B	7.27B
Investing Cash Flow	0.00	1.82B	-4.16B	-1.48B	-3.96B	-718.20M
Financing Cash Flow	0.00	-9.25B	-7.45B	-6.39B	-6.37B	-5.82B

Abbott India Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 29697.25
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ABBOTINDIA, the sentiment is Negative. The current price of 29697.25 is below the 20-day moving average (MA) of 29883.50, below the 50-day MA of 30730.02, and below the 200-day MA of 30547.41, indicating a bearish trend. The MACD of -234.92 indicates Negative momentum. The RSI at 40.68 is Neutral, neither overbought nor oversold. The STOCH value of 19.98 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ABBOTINDIA.

Abbott India Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUROPHARMA	―	₹630.26B	18.58	―	0.36%	7.76%	-2.84%
LUPIN	―	₹893.78B	23.70	―	0.61%	12.40%	63.16%
ZYDUSLIFE	―	₹993.45B	21.73	―	1.10%	14.52%	9.46%
ABBOTINDIA	―	₹635.62B	43.61	―	1.60%	11.17%	17.22%
GLAXO	―	₹465.11B	48.87	―	2.04%	6.65%	48.47%
BIOCON	―	₹498.48B	114.16	―	0.13%	6.80%	-75.66%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%